Signatope

Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.

Pressemeldungen

High-Tech Gründerfonds (HTGF) invests in Reutlingen-based SIGNATOPE GmbH – Safe medications thanks to new test procedures

High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection…
Read

Info & Contact

Dr. Oliver Pötz
+49 712 1515 308 02
Web:
www.signatope.de

Address

Signatope GmbH
Markwiesenstr. 55
72770 Reutlingen

In portfolio

14. Nov 2016